Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 26
Filtrar
Más filtros

Medicinas Complementárias
Tipo del documento
Intervalo de año de publicación
1.
Artículo en Inglés | MEDLINE | ID: mdl-29310888

RESUMEN

We present the case of a 32-year-old male patient complaining of recurrent mandibular pain for 3.5 years. Panoramic radiography indicated increased cortical density of the mandibular lower border. Scintigraphy and single-photon emission computed tomography revealed metabolic hyperactivity in that region without pathologic lymph nodes. A bone biopsy specimen of the mandibular lower border did not have inflammation or cytologic atypia. Endocrinologic investigation confirmed secondary hyperparathyroidism as a result of hypovitaminosis D. Several weeks after starting therapy with oral vitamin D supplements, the symptoms completely disappeared. Increased cortical density is a rare manifestation of secondary hyperparathyroidism, which normally causes the lamina dura to vanish and produces a ground-glass appearance as a result of blurring of the trabecular bone pattern. Because focal hyperostosis can have multiple benign or malignant causes, radiologic examination of the jaw bones is indispensable for evaluating orofacial pain. Increased cortical density may be caused by metabolic diseases, requiring further investigations, including biopsy and blood analysis.


Asunto(s)
Hiperparatiroidismo Secundario/tratamiento farmacológico , Hiperparatiroidismo Secundario/etiología , Enfermedades Mandibulares/diagnóstico por imagen , Enfermedades Mandibulares/tratamiento farmacológico , Deficiencia de Vitamina D/diagnóstico por imagen , Deficiencia de Vitamina D/prevención & control , Vitamina D/uso terapéutico , Adulto , Biopsia , Densidad Ósea , Diagnóstico Diferencial , Humanos , Masculino , Dimensión del Dolor , Radiografía Panorámica , Tomografía Computarizada de Emisión de Fotón Único
2.
Tissue Eng Part A ; 24(11-12): 943-954, 2018 06.
Artículo en Inglés | MEDLINE | ID: mdl-29264958

RESUMEN

A tissue engineering approach to address craniofacial defects requires a biomaterial that balances macro-scale mechanical stiffness and strength with the micron-scale features that promote cell expansion and tissue biosynthesis. Such criteria are often in opposition, leading to suboptimal mechanical competence or bioactivity. We report the use of a multiscale composite biomaterial that integrates a polycaprolactone (PCL) reinforcement structure with a mineralized collagen-glycosaminoglycan scaffold to circumvent conventional tradeoffs between mechanics and bioactivity. The composite promotes activation of the canonical bone morphogenetic protein 2 (BMP-2) pathway and subsequent mineralization of adipose-derived stem cells in the absence of supplemental BMP-2 or osteogenic media. We subsequently examined new bone infill in the acellular composite, scaffold alone, or PCL support in 10 mm dia. ramus mandibular defects in Yorkshire pigs. We report an analytical approach to quantify radial, angular, and depth bone infill from micro-computed tomography data. The collagen-PCL composite showed improved overall infill, and significantly increased radial and angular bone infill versus the PCL cage alone. Bone infill was further enhanced in the composite for defects that penetrated the medullary cavity, suggesting recruitment of marrow-derived cells. These results indicate a multiscale mineralized collagen-PCL composite offers strategic advantages for regenerative repair of craniofacial bone defects.


Asunto(s)
Colágeno/química , Enfermedades Mandibulares/tratamiento farmacológico , Poliésteres/química , Animales , Huesos/patología , Enfermedades Mandibulares/metabolismo , Porcinos , Cicatrización de Heridas/efectos de los fármacos
3.
Bauru; s.n; 2017. 89 p. ilus, tab, graf.
Tesis en Portugués | LILACS, BBO | ID: biblio-883240

RESUMEN

Os bisfosfonatos (BF) são amplamente utilizados no tratamento de doenças osteolíticas como metástases ósseas e osteoporose. A osteonecrose dos maxilares associada ao uso de BF (OMAB) é caracterizada pela presença de osso exposto ou que pode ser sondado através de uma fístula que persiste por mais de oito semanas em pacientes com história de terapia de BF e sem história de radioterapia na região de cabeça e pescoço e/ou sem doença metastática nos maxilares. A incidência de OMAB aumenta com a potência, duração do tratamento e dose de BF recebida. Até o presente momento, a fisiopatologia da OMAB não está clara, dificultando a prevenção e o tratamento. O objetivo deste estudo foi avaliar o efeito da administração de altas doses Ácido Zoledrônico (AZ) por período prolongado no osso esponjoso da mandíbula e da metáfise proximal do fêmur de ratos Wistar. Para relacionar as descobertas à fisiopatologia da OMAB, o regime de administração de BF de um modelo animal relevante desta lesão foi reproduzido. Seis animais receberam AZ (0,6 mg / kg) e seis receberam solução salina no mesmo volume (Controles). Os compostos foram administrados por via intraperitoneal em cinco doses a cada 28 dias. A eutanásia dos animais ocorreu após 150 dias de início da terapia. As hemimandíbulas e fêmures direitos foram escaneados usando Micro-tomografia computadorizada (Micro-CT) de alta resolução (14 m). Para a primeira análise realizada neste estudo, os dados morfométricos do osso esponjoso foram calculados na região do segundo e primeiro molar na mandíbula e na metáfise do fêmur usando CTAnalyzer (Bruker, Bélgica). Para a segunda análise, cinco amostras de hemimandíbulas de cada grupo foram cortadas em lâminas histológicas (5 m) e coradas com Hematoxilina e Eosina. Para comparar os parâmetros morfométricos na Micro-CT e histologia, as imagens de Micro-CT foram espacialmente alinhadas à histologia. Os dados morfométricos do osso alveolar foram calculados usando o software CTAnalyzer (Bruker, Bélgica) na região entre as raízes mesial e distal do primeiro molar. A densidade da área vascular (área vascular/área total; VA/TA) e os dados histomorfométricos ósseos foram estimados usando Axiovision na mesma região (entre as raízes mesial e distal do primeiro molar). Foi adotada significância estatística de 5% ( = 0,05). Os animais tratados com AZ apresentaram aumento significativo na porcentagem de volume ósseo (p <0,05) com trabéculas mais espessas, osso mais compacto com menor separação trabecular na mandíbula e no fêmur. Na mandíbula, o aumento da densidade óssea e diminuição da separação trabecular foram fortemente correlacionados com a diminuição da área vascular observada no grupo AZ (p <0,05). Em conclusão, o tratamento de longa duração com altas doses de AZ foi significativamente associado ao aumento na densidade óssea e à diminuição dos espaços medulares, canais nutritivos e vasculatura do osso alveolar. A análise com Micro-CT revelou alterações semelhantes na estrutura óssea tanto na mandíbula quanto no fêmur do grupo AZ.(AU)


Bisphosphonates (BFs) are widely used in the treatment of osteolytic diseases such as bone metastases and osteoporosis. The osteonecrosis of the jaws related to BF (ONB) is characterized by the presence of exposed bone or bone that can be probed through a fistula that persists for more than eight weeks in patients with a history of BF therapy and without history of head and neck radiotherapy and / or without metastatic disease in the jaws. The incidence of ONB increases with potency, duration of treatment and dose of BF received. Thus far, the pathophysiology of ONB is unclear, hampering prevention and treatment. The aim of this study was to objectively assess the effect of long-term high-dose Zoledronic Acid (ZA) on cancellous bone in the jaw and femur of Wistar rats. In order to link our findings to the physiopathology of ONB, the therapeutic regiment of a relevant ONB animal model was reproduced. Twelve Wistar rats were randomly divided in two groups: six received Zoledronic acid (ZA; 0.6 mg / kg) and six (Controls) received saline solution in the same volume. The compounds were administrated intraperitoneally in five doses each 28 days. The rats were killed after 150 days of the therapy onset. Mandibles and femurs were scanned using a high-resolution (14m) micro-computerized tomography (Micro-CT). For the first analysis carried in this study, cancellous bone morphometric data were calculates in the region of the second and first molar in the mandible and in the proximal femur using CTAnalyzer (Bruker, Belgium). For the second analysis five samples were cut into histological slices (5m) and stained with Hematoxylin and Eosin. In order to compare the same morphological structures in Micro-CT and histology, the Micro-CT images were aligned to histology. Alveolar bone morphometric data (Micro-CT) was calculated using CTAnalyzer (Bruker, Belgium) in the region between the mesial and distal roots of the first molar. Blood vessels density and bone histomorphometric data were calculated using Axiovision (Carl Zeiss, Germany) in the same region used for Micro-CT evaluation. Statistical significance of 5% (=0.05) was adopted. ZA treated rats presented significant increase in the percentage of bone volume (p<0.05) with thicker trabeculae and more compact bone with smaller marrow spaces in the mandible and femur. In the mandible, the increase in bone density and decrease of marrow spaces size was strongly correlated with the decrease in the vascular area noticed in the ZA group (p<0.05). In conclusion, long-term high-dose ZA treatment was significant associated with the increase of bone density and the diminution of medullary spaces and nutritive canals size as well as decrease in vascularity of the alveolar bone. Micro-CT investigation showed similar changes in bone structure in the mandible and femur in the ZA group.(AU)


Asunto(s)
Animales , Ratas , Osteonecrosis de los Maxilares Asociada a Difosfonatos/tratamiento farmacológico , Conservadores de la Densidad Ósea/administración & dosificación , Hueso Esponjoso/efectos de los fármacos , Difosfonatos/administración & dosificación , Fémur/efectos de los fármacos , Imidazoles/administración & dosificación , Enfermedades Mandibulares/tratamiento farmacológico , Osteonecrosis de los Maxilares Asociada a Difosfonatos/fisiopatología , Densidad Ósea , Distribución Aleatoria , Ratas Wistar , Reproducibilidad de los Resultados , Factores de Tiempo , Resultado del Tratamiento , Microtomografía por Rayos X
4.
J Clin Periodontol ; 42(1): 96-103, 2015 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-25469560

RESUMEN

AIM: Vitamin D deficiency is considered to diminish bone regeneration. Yet, raising the serum levels takes months. A topic application of the active vitamin D metabolite, calcitriol, may be an effective approach. Thus, it becomes important to know the effect of vitamin D deficiency and local application on alveolar bone regeneration. MATERIAL AND METHODS: Sixty rats were divided into three groups; two vitamin depletion groups and a control group. Identical single defects (2 mm diameter) were created in the maxilla and mandible treated with calcitriol soaked collagen in one deficiency group while in the other two groups not. Histomorphometric analysis and micro CTs were performed after 1 and 3 weeks. Serum levels of 25(OH)D3 and PTH were determined. RESULTS: Bone formation rate significantly increased within the observation period in all groups. Bone regeneration was higher in the maxilla than in the mandible. However, bone regeneration was lower in the control group compared to vitamin depletion groups, with no significant effects by local administration of calcitriol (micro CT mandible p = 0.003, maxilla p < 0.001; histomorphometry maxilla p = 0.035, mandible p = 0.18). CONCLUSION: Vitamin D deficiency not necessarily impairs bone regeneration in the rat jaw and a single local calcitriol application does not enhance healing.


Asunto(s)
Pérdida de Hueso Alveolar/tratamiento farmacológico , Conservadores de la Densidad Ósea/administración & dosificación , Regeneración Ósea/efectos de los fármacos , Calcitriol/administración & dosificación , Deficiencia de Vitamina D/complicaciones , Administración Tópica , Pérdida de Hueso Alveolar/patología , Proceso Alveolar/efectos de los fármacos , Proceso Alveolar/patología , Animales , Matriz Ósea/efectos de los fármacos , Matriz Ósea/patología , Calcifediol/sangre , Calcificación Fisiológica/efectos de los fármacos , Masculino , Enfermedades Mandibulares/tratamiento farmacológico , Enfermedades Mandibulares/patología , Enfermedades Maxilares/tratamiento farmacológico , Enfermedades Maxilares/patología , Tamaño de los Órganos , Osteoblastos/efectos de los fármacos , Osteoblastos/patología , Osteogénesis/efectos de los fármacos , Hormona Paratiroidea/sangre , Ratas , Ratas Sprague-Dawley , Factores de Tiempo , Microtomografía por Rayos X/métodos
5.
Br J Oral Maxillofac Surg ; 52(4): 356-62, 2014 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-24480621

RESUMEN

This study is a retrospective review of treatment outcomes of osteoradionecrosis (ORN) of the mandible with specific reference to the evolving role of medical management with pentoxifylline, tocopherol, and doxycycline. We reviewed the presentation and management of 71 patients treated for ORN of the mandible at the regional head and neck unit during a 15-year period to January 2011, and categorised them into three grades using the Notani classification: grade I (n=28), grade II (n=16), and grade III (n=27). Twelve patients with grade I ORN, 3 with grade II, and 10 with grade III, were prescribed medical treatment. Of these, three with grade I, and two with grade II ORN were cured, and progression of the disease had halted and there was satisfactory control of symptoms in eight with grade I and four with grade III disease. Patients who failed to respond to conservative treatment were further analysed for the need for free flap reconstruction. Medical management was introduced as a standard treatment in January 2006. Of the 39 patients diagnosed before this, 20 (51%) required resection and free flap reconstruction compared with only 8/32 (25%) after it had been introduced.


Asunto(s)
Enfermedades Mandibulares/tratamiento farmacológico , Osteorradionecrosis/tratamiento farmacológico , Anciano , Anciano de 80 o más Años , Antibacterianos/uso terapéutico , Antioxidantes/uso terapéutico , Carcinoma de Células Escamosas/radioterapia , Desbridamiento/métodos , Progresión de la Enfermedad , Doxiciclina/uso terapéutico , Femenino , Estudios de Seguimiento , Colgajos Tisulares Libres/trasplante , Humanos , Oxigenoterapia Hiperbárica/métodos , Masculino , Enfermedades Mandibulares/clasificación , Persona de Mediana Edad , Procedimientos Quirúrgicos Mínimamente Invasivos/métodos , Osteorradionecrosis/clasificación , Pentoxifilina/uso terapéutico , Protectores contra Radiación/uso terapéutico , Procedimientos de Cirugía Plástica/métodos , Inducción de Remisión , Estudios Retrospectivos , Tocoferoles/uso terapéutico , Resultado del Tratamiento
6.
Minerva Stomatol ; 63(1-2): 35-41, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24487948

RESUMEN

Bisphosphonate induced necrosis of the jaws (BONJ) does not have a unique protocol of treatment and many therapeutic approaches have been arising in oral medicine with debatable results. A male and a female attended the University Oral Surgery Clinic presenting oral bone lesions induced by intravenous and oral bisphosphonates respectively as complications of dental extraction. Treatment included daily mouthwashes and weekly intra oral irrigations with 4 mg/L of aqueous-ozone, antibiotic therapy and sequential superficial debridment for sequestrectomies. Long-standing follow-ups showed complete mucosa covering of exposed bone area and resolution of purulent secretion. Antibacterial and antifungal properties of aqueous ozone may have played important roles in the treatment. The outcome measured intra oral examination and panoramic radiographs of the affected bone. The application of aqueous ozone daily mouthwashes and weekly professional irrigation were safe; free from adverse effects, easily of handling and worked as an important adjuvant therapeutic strategy for the treatment of BONJ.


Asunto(s)
Antiinfecciosos/uso terapéutico , Osteonecrosis de los Maxilares Asociada a Difosfonatos/tratamiento farmacológico , Quimioterapia Adyuvante , Ozono/uso terapéutico , Anciano , Antibacterianos/uso terapéutico , Antiinfecciosos/administración & dosificación , Antiinfecciosos Locales/administración & dosificación , Antiinfecciosos Locales/uso terapéutico , Osteonecrosis de los Maxilares Asociada a Difosfonatos/cirugía , Neoplasias Óseas/tratamiento farmacológico , Neoplasias Óseas/secundario , Clorhexidina/administración & dosificación , Clorhexidina/análogos & derivados , Clorhexidina/uso terapéutico , Clindamicina/uso terapéutico , Terapia Combinada , Desbridamiento , Difosfonatos/efectos adversos , Difosfonatos/uso terapéutico , Femenino , Humanos , Imidazoles/efectos adversos , Imidazoles/uso terapéutico , Masculino , Enfermedades Mandibulares/inducido químicamente , Enfermedades Mandibulares/tratamiento farmacológico , Enfermedades Mandibulares/cirugía , Enfermedades Maxilares/inducido químicamente , Enfermedades Maxilares/tratamiento farmacológico , Enfermedades Maxilares/cirugía , Persona de Mediana Edad , Antisépticos Bucales , Osteoporosis Posmenopáusica/tratamiento farmacológico , Ozono/administración & dosificación , Neoplasias de la Próstata , Solubilidad , Ácido Zoledrónico
7.
Artículo en Inglés | MEDLINE | ID: mdl-22668439

RESUMEN

The radiation-induced fibroatrophic process (RIF) is a time-dependent adverse sequela to high-dose radiotherapy that can result in irreversible tissue death and bone exposure in the irradiated tissue. Osteoradionecrosis (ORN) is a late effect of RIF, described as bony exposure present for more than 3 months that can occur in 20% of patients irradiated for head and neck cancer. The intractable characteristics of ORN make both management and resolution of the disease process challenging, with 25% of cases recurring despite aggressive treatment with resection and reconstruction of the necrotic bone. In this article, we present a case of a 66-year-old man with unevoked ORN of the left posterior lingual mandibular cortex that was successfully treated and resolved with 6 months of pentoxifylline 400 mg twice a day and tocopherol 1000 IU every day.


Asunto(s)
Antioxidantes/uso terapéutico , Enfermedades Mandibulares/tratamiento farmacológico , Osteorradionecrosis/tratamiento farmacológico , Pentoxifilina/uso terapéutico , alfa-Tocoferol/uso terapéutico , Anciano , Irradiación Craneana/efectos adversos , Combinación de Medicamentos , Humanos , Masculino , Enfermedades Mandibulares/etiología , Osteorradionecrosis/etiología , Neoplasias de la Lengua/tratamiento farmacológico , Neoplasias de la Lengua/radioterapia , Neoplasias Tonsilares/tratamiento farmacológico , Neoplasias Tonsilares/radioterapia
8.
Implant Dent ; 20(5): 331-6, 2011 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-21881516

RESUMEN

Osteonecrosis of the jaws (ONJ) is a condition characterized by necrotic exposed bone in the jaws of patients receiving intravenous or oral bisphosphonate therapy. A review of the medical and dental literature reveals that the pathoetiology of ONJ remains unknown and there is no established link that bisphosphonates are the primary cause of this bone pathology. However, there is clinical evidence that Actinomyces may play a critical role in the pathogenesis of bisphosphonate-associated ONJ. Identification and a prolonged course of oral antimicrobial therapy may lead to complete resolution of this actinomycotic osteonecrosis.


Asunto(s)
Actinomicosis/diagnóstico , Osteonecrosis de los Maxilares Asociada a Difosfonatos/microbiología , Enfermedades Mandibulares/microbiología , Enfermedades Maxilares/microbiología , Actinomyces/clasificación , Actinomicosis/tratamiento farmacológico , Anciano , Anciano de 80 o más Años , Antibacterianos/uso terapéutico , Biopsia , Osteonecrosis de los Maxilares Asociada a Difosfonatos/tratamiento farmacológico , Clindamicina/uso terapéutico , Estudios de Cohortes , Desbridamiento , Doxiciclina/uso terapéutico , Eritromicina/uso terapéutico , Femenino , Humanos , Oxigenoterapia Hiperbárica , Masculino , Enfermedades Mandibulares/tratamiento farmacológico , Enfermedades Maxilares/tratamiento farmacológico , Persona de Mediana Edad , Penicilina V/uso terapéutico , Plasma Rico en Plaquetas , Estudios Prospectivos , Resultado del Tratamiento
9.
Int J Radiat Oncol Biol Phys ; 80(3): 832-9, 2011 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-20638190

RESUMEN

PURPOSE: Osteoradionecrosis (ORN) is a nonhealing wound of the bone that is difficult to manage. Combined treatment with pentoxifylline and vitamin E reduces radiation-induced fibrosis and ORN with a good prognosis. We previously showed that the combination of pentoxifylline and vitamin E with clodronate (PENTOCLO) is useful in healing sternocostal and some mandibular ORN. Is PENTOCLO effective in ORN of poor prognosis? METHODS: 54 eligible patients previously irradiated for head and neck cancer (among 72 treated) a mean 5 years previously received exteriorized refractory mandibular ORN for 1.4 ± 1.8 years, mainly after local surgery and hyperbaric oxygen had been ineffective. The mean length of exposed bone (D) was 17 ± 8 mm as primary endpoint, and the mean Subjective, Objective, Management, and Analytic evaluation of injury (SOMA) score was 16 ± 4. Between August 2000 and August 2008, all patients were given daily oral PENTOCLO: 800 mg pentoxifylline, 1,000 IU vitamin E, and 1,600 mg clodronate 5 days per week alternating with 20 mg prednisone and 1,000 mg ciprofloxacin 2 days per week. The duration of treatment was related to consolidated healing. RESULTS: Prolonged treatment (16 ± 9 months) was safe and well tolerated. All patients improved, with an exponential progressive--(f[t] = a.exp(-b.t)--and significant (p < 0.0001) reduction of exposed bone (D), respectively (months): D(2) -42%, D(4) -62%, D(6) -77%, D(12) -92%, and D(18) -96%, combined with iterative spontaneous sequestrectomies in 36 patients. All patients experienced complete recovery in a median of 9 months. Clinical improvement was measured in terms of discontinuation of analgesics, new fracture, closed skin fistulae, and delayed radiologic improvement: SOMA(6) -64%, SOMA(12) -89%, and SOMA(30) -96%. CONCLUSION: Long-term PENTOCLO treatment is effective, safe, and curative for refractory ORN and induces mucosal and bone healing with significant symptom improvement. These findings will need to be confirmed in a randomized trial.


Asunto(s)
Conservadores de la Densidad Ósea/uso terapéutico , Ácido Clodrónico/uso terapéutico , Enfermedades Mandibulares/tratamiento farmacológico , Osteorradionecrosis/tratamiento farmacológico , Pentoxifilina/uso terapéutico , Tocoferoles/uso terapéutico , Adulto , Anciano , Anciano de 80 o más Años , Ciprofloxacina/uso terapéutico , Esquema de Medicación , Combinación de Medicamentos , Femenino , Neoplasias de Cabeza y Cuello/radioterapia , Humanos , Masculino , Persona de Mediana Edad , Prednisona/uso terapéutico , Pronóstico
10.
South Med J ; 101(5): 539-40, 2008 May.
Artículo en Inglés | MEDLINE | ID: mdl-18414152

RESUMEN

Multidrug-resistant viridans group streptococcus (MDRVS) strains have emerged as important pathogens. Treatment of MDRVS infections is problematic. The use of fluoroquinolones for treatment of MDRVS osteomyelitis has not been established. We present the first case of MDRVS osteomyelitis of the mandible successfully treated with sequential intravenous then oral moxifloxacin, and review the literature on the subject.


Asunto(s)
Antiinfecciosos/uso terapéutico , Compuestos Aza/uso terapéutico , Farmacorresistencia Bacteriana Múltiple , Enfermedades Mandibulares/tratamiento farmacológico , Enfermedades Mandibulares/microbiología , Osteomielitis/tratamiento farmacológico , Osteomielitis/microbiología , Quinolinas/uso terapéutico , Infecciones Estreptocócicas/tratamiento farmacológico , Estreptococos Viridans , Adulto , Antiinfecciosos/administración & dosificación , Antiinfecciosos/farmacología , Compuestos Aza/administración & dosificación , Compuestos Aza/farmacología , Desbridamiento , Femenino , Fluoroquinolonas , Humanos , Enfermedades Mandibulares/cirugía , Moxifloxacino , Osteomielitis/cirugía , Quinolinas/administración & dosificación , Quinolinas/farmacología , Estreptococos Viridans/efectos de los fármacos
11.
J Periodontal Res ; 43(1): 14-21, 2008 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-18230102

RESUMEN

BACKGROUND AND OBJECTIVE: Baicalin is a flavonoid compound purified from the medicinal plant, Scutellaria baicalensis Georgi, and has been reported to possess anti-inflammatory and antioxidant activities. The purpose of this study was to test the ability of baicalin to influence the progression of experimental periodontitis in rats, as well as the expression of cyclooxygenase-2 and inducible nitric oxide synthase. MATERIAL AND METHODS: Adult male Sprague-Dawley rats were subjected to placement of a nylon thread around the bilateral lower first molars and killed after 7 d. Baicalin (50, 100 or 200 mg/kg) was supplied to the animals by oral gavage, starting 1 d before the induction of periodontitis. The ligature group consisted of rats subjected to periodontitis and receiving vehicle (0.5% carboxymethylcellulose) alone. The alveolar bone loss and the area fraction occupied by collagen fibers were assessed. The expression of cyclooxygenase-2 and inducible nitric oxide synthase protein in the gingiva were detected by immunohistochemistry and western blotting. RESULTS: Baicalin-treated groups presented with lower alveolar bone loss than that of the ligature group, reaching statistical significance at the dose of 200 mg/kg (p = 0.009). The area fraction of collagen fibers was significantly higher in the baicalin (200 mg/kg)-treated group than in the ligature group (p = 0.047). Baicalin treatment significantly down-regulated the protein expression for cyclooxygenase-2 (p = 0.000) and inducible nitric oxide synthase (p = 0.003), compared with the ligature group. CONCLUSION: Baicalin protects against tissue damage in ligature-induced periodontitis in rats, which might be mediated, in part, by its inhibitory effect on the expression of cyclooxygenase-2 and inducible nitric oxide synthase. These activities could support the continued investigation of baicalin as a potential therapeutic agent in periodontal disease.


Asunto(s)
Pérdida de Hueso Alveolar/tratamiento farmacológico , Antiinflamatorios no Esteroideos/uso terapéutico , Ciclooxigenasa 2/efectos de los fármacos , Flavonoides/uso terapéutico , Óxido Nítrico Sintasa de Tipo II/efectos de los fármacos , Periodontitis/tratamiento farmacológico , Pérdida de Hueso Alveolar/prevención & control , Animales , Ciclooxigenasa 2/metabolismo , Encía/química , Encía/efectos de los fármacos , Ligadura , Masculino , Enfermedades Mandibulares/tratamiento farmacológico , Enfermedades Mandibulares/prevención & control , Óxido Nítrico Sintasa de Tipo II/metabolismo , Periodontitis/etiología , Ratas , Ratas Sprague-Dawley
12.
J Clin Periodontol ; 35(2): 147-56, 2008 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-18081859

RESUMEN

AIM: The aim of this study was to evaluate the immediate post-operative pain, wound healing and clinical results after the application of an enamel matrix protein derivative (EMD) alone or combined with a low-level laser therapy (LLLT) for the treatment of deep intra-bony defects. MATERIAL AND METHODS: This study was an intra-individual longitudinal test of 12 months' duration conducted using a blinded, split-mouth, placebo-controlled and randomized design. In 22 periodontitis patients, one intra-bony defect was randomly treated with EMD+LLLT, while EMD alone was applied to the contra-lateral defect site. LLLT was used both intra- and post-operatively. Clinical measurements were performed by a blinded periodontist at the time of surgery, in the first week and in the first, second, sixth and 12th month. Visual analogue scale (VAS) scores were recorded for pain assessment. RESULTS: The results have shown that the treatment of intra-bony defects with EMD alone or EMD+LLLT leads to probing depth reduction and attachment-level gain. In addition, EMD+LLLT had resulted in less gingival recession (p<0.05), less swelling (p<0.001) and less VAS scores (p<0.02) compared with EMD alone. CONCLUSION: This study shows that EMD is an effective, safe and predictable biomaterial for periodontal regeneration and LLLT may improve the effects of EMD by reducing post-operative complications.


Asunto(s)
Pérdida de Hueso Alveolar , Sustitutos de Huesos/uso terapéutico , Proteínas del Esmalte Dental/uso terapéutico , Terapia por Luz de Baja Intensidad/métodos , Adulto , Pérdida de Hueso Alveolar/tratamiento farmacológico , Pérdida de Hueso Alveolar/radioterapia , Terapia Combinada/métodos , Métodos Epidemiológicos , Femenino , Humanos , Masculino , Enfermedades Mandibulares/tratamiento farmacológico , Enfermedades Mandibulares/radioterapia , Enfermedades Maxilares/tratamiento farmacológico , Enfermedades Maxilares/radioterapia , Persona de Mediana Edad , Dolor Postoperatorio/epidemiología , Resultado del Tratamiento , Cicatrización de Heridas/efectos de los fármacos
13.
Int J Oral Maxillofac Surg ; 35(9): 865-9, 2006 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-16584870

RESUMEN

Central giant cell granuloma (CGCG) is a benign lesion of the jaws with a sometimes locally aggressive behaviour. The most common therapy is surgical curettage which has a high recurrence rate, especially in lesions with aggressive signs and symptoms (i.e. pain, paresthesia, root-resorption and rapid growth). Alternative therapies such as interferon alpha (INFalpha) or calcitonin are described in the literature. In this study 2 patients with an aggressive CGCG are presented who were treated with INF mono-therapy. INF mono-therapy was capable of terminating the rapid growth of the lesion in both patients and induced a partial reduction. Total resolution, however, was not obtained and alternative treatment is still necessary.


Asunto(s)
Granuloma de Células Gigantes/tratamiento farmacológico , Interferón-alfa/uso terapéutico , Enfermedades Mandibulares/tratamiento farmacológico , Enfermedades Maxilares/tratamiento farmacológico , Adolescente , Adulto , Conservadores de la Densidad Ósea/administración & dosificación , Conservadores de la Densidad Ósea/uso terapéutico , Calcitonina/uso terapéutico , Femenino , Granuloma de Células Gigantes/diagnóstico por imagen , Humanos , Interferón-alfa/administración & dosificación , Masculino , Mandíbula/diagnóstico por imagen , Enfermedades Mandibulares/diagnóstico por imagen , Maxilar/diagnóstico por imagen , Enfermedades Maxilares/diagnóstico por imagen , Radiografía , Inducción de Remisión/métodos , Insuficiencia del Tratamiento
14.
J Clin Periodontol ; 32(10): 1062-8, 2005 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16174269

RESUMEN

BACKGROUND: Recent studies have demonstrated that Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl), a cell membrane-permeable radical scavenger, exerts protective effects in various models of inflammation and shock. Reactive oxygen species (ROS) plays a pivotal role in the induction of genes involved in physiological processes as well as in the response to inflammation. AIM: We have investigated the effect of Tempol in a rat model of periodontitis. MATERIALS AND METHODS: Periodontitis was induced in rats by placing a 2/0 braided silk ligature around the lower left first molar. At day 8, the gingivomucosal tissue encircling the mandibular first molar was removed for evaluation of neutrophils infiltration, tissue permeability, nitrotyrosine formation, poly-(ADP-ribose) polymerase (PARP) activation, radiography and histology. RESULTS AND CONCLUSIONS: Legation significantly induced an increased neutrophil infiltration and a positive staining for nitrotyrosine formation and PARP activation. Ligation significantly increased Evans blue extravasation in gingivomucosal tissue and alveolar bone erosion as evaluated by radiography analysis. Intraperitonial injection of Tempol (10 mg/kg daily for 8 days) significantly decreased all of the parameters of inflammation as described above. This suggests that antioxidant therapies, which interfere with ROS, may be of benefit in the treatment of periodontitis.


Asunto(s)
Pérdida de Hueso Alveolar/tratamiento farmacológico , Óxidos N-Cíclicos/uso terapéutico , Depuradores de Radicales Libres/uso terapéutico , Enfermedades Mandibulares/tratamiento farmacológico , Periodontitis/tratamiento farmacológico , Animales , Evaluación Preclínica de Medicamentos , Masculino , Modelos Animales , Periodontitis/enzimología , Poli(ADP-Ribosa) Polimerasas/efectos de los fármacos , Distribución Aleatoria , Ratas , Ratas Sprague-Dawley , Marcadores de Spin , Tirosina/análogos & derivados , Tirosina/efectos de los fármacos
15.
Eur J Oral Sci ; 113(1): 47-52, 2005 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-15693829

RESUMEN

We studied the effect of dietary supplementation with grape seed proanthocyanidins extract (GSPE) 3 mg added in 100 g high-calcium diet with a calcium content of 1697 mg 100 g(-1) on mandibular condyle bone debility, which was induced by a low-calcium diet. Forty Wistar male rats, 5 week old, were randomly divided into control (Co), low-calcium diet (LC), low-calcium/high-calcium diet (LCH), and low-calcium/high-calcium with supplementary GSPE diet (LCHG) groups for 6 wk. Bone formation of the mandibular condyle was measured using peripheral quantitative computed tomography (pQCT). Significant differences were not seen among the four groups for body weight, measured weekly. The LCHG group scored significantly higher in cortical bone density, total bone cross-sectional area, cortical bone cross-sectional area, cortical bone mineral content, total bone density, total bone mineral content, and in the stress-strain index to the reference axis x when compared with the LCH group. We concluded that a high-calcium diet combined with GSPE supplementation is more effective in reversing mandibular condyle bone debility in rats than is a low-calcium diet, standard diet, or high-calcium diet alone.


Asunto(s)
Cóndilo Mandibular/efectos de los fármacos , Enfermedades Mandibulares/tratamiento farmacológico , Osteogénesis/efectos de los fármacos , Fitoterapia , Extractos Vegetales/uso terapéutico , Proantocianidinas/uso terapéutico , Semillas , Vitis , Anatomía Transversal , Animales , Peso Corporal/efectos de los fármacos , Densidad Ósea/efectos de los fármacos , Calcio/deficiencia , Calcio de la Dieta/uso terapéutico , Elasticidad , Masculino , Cóndilo Mandibular/diagnóstico por imagen , Enfermedades Mandibulares/diagnóstico por imagen , Minerales/análisis , Distribución Aleatoria , Ratas , Ratas Wistar , Estrés Mecánico , Tomografía Computarizada por Rayos X
16.
J Periodontol ; 75(6): 811-6, 2004 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-15295946

RESUMEN

BACKGROUND: We have previously reported that estrogen/hormone replacement therapy (E/HRT) has beneficial effects on oral bone density over 3 years and that calcium and vitamin D supplementation has a lesser effect. Here we report on mandibular bone mass for 49 women (of the original cohort of 135) who continued in an additional 2-year, open-label extension. METHODS: Postmenopausal women were randomly assigned to receive calcium and vitamin D plus E/HRT, or calcium and vitamin D only. Regression analysis of mandibular bone mass over time was performed for each woman. RESULTS: Twenty-two of 26 women who took calcium and vitamin D plus E/HRT for 5 years had small mandibular bone mass increases (0.35 +/- 0.38%, P<0.001). Seventeen of 19 women who took only calcium and vitamin D for 3 years had increases in mandibular bone mass (0.74 +/- 0.89%, P<0.002). The largest gains in mandibular bone mass occurred during the first 3 years of the study. CONCLUSIONS: The data of this study indicate that E/HRT and/or calcium and vitamin D may result in increases of mandibular bone mass in postmenopausal women. Because of the long-term risks associated with E/HRT, caution should be exercised in prescribing E/HRT for prevention of chronic menopausal conditions.


Asunto(s)
Pérdida de Hueso Alveolar/tratamiento farmacológico , Densidad Ósea/efectos de los fármacos , Calcio/administración & dosificación , Terapia de Reemplazo de Estrógeno , Vitamina D/administración & dosificación , Análisis de Varianza , Protocolos Clínicos , Método Doble Ciego , Combinación de Medicamentos , Femenino , Humanos , Modelos Logísticos , Mandíbula/diagnóstico por imagen , Mandíbula/efectos de los fármacos , Enfermedades Mandibulares/tratamiento farmacológico , Persona de Mediana Edad , Posmenopausia , Radiografía
17.
J Oral Sci ; 44(2): 85-90, 2002 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-12227500

RESUMEN

In the treatment of diabetes-induced pathologies, beneficial results have been obtained with administration of antioxidants. Selenium is an antioxidant and essential trace element in living organisms. The aim of this study was to investigate the possible effects of selenium on the structural alterations of the mandible due to diabetes. In this study thirty-nine Wistar rats were used and a control, a selenium given control, a diabetic and a selenium given diabetes groups were formed. Experimental diabetes was induced by a single i.p. injection (50 mg/kg) of streptozotocin (STZ). The diabetic + selenium and the control + selenium groups were injected with a daily dose of 5 micro mol/kg/day sodium selenite (i.p.) for 4 weeks while the diabetic and the control groups were injected with distilled water. Mandibles of all the animals were excised and examined at the 5th week. High blood glucose level and low body weight in the diabetic group were not significantly affected by selenium administration. Furthermore, a negligible increase in blood glucose level was observed in the selenium given control group. Densitometric analysis revealed a significant reduction in bone density and presence of resorption in the diabetic and the selenium given control groups as compared to the selenium given diabetes and the control groups. In X-ray diffraction analysis, the reduction in peak intensity of the reflected light in both the diabetic and the selenium given control groups indicated a possible alteration in the crystallinity or a poor crystalline substance. Histological investigation showed that there was progressive resorption, trabecular and cortical irregularity and vascular proliferation in the diabetic and the selenium given control groups, whereas a more healthy appearance was detected in the selenium given diabetes group. The results of this study suggest the positive effects of selenium on diabetes-induced structural alterations in the mandible. However, the unexpected results in the selenium given control group necessitate further studies on the mechanism of selenium effects in organisms.


Asunto(s)
Proceso Alveolar/efectos de los fármacos , Antioxidantes/farmacología , Densidad Ósea/efectos de los fármacos , Diabetes Mellitus Experimental/tratamiento farmacológico , Mandíbula/efectos de los fármacos , Selenio/farmacología , Absorciometría de Fotón , Proceso Alveolar/irrigación sanguínea , Proceso Alveolar/patología , Animales , Antioxidantes/uso terapéutico , Diabetes Mellitus Experimental/inducido químicamente , Diabetes Mellitus Experimental/patología , Mandíbula/irrigación sanguínea , Mandíbula/patología , Enfermedades Mandibulares/tratamiento farmacológico , Enfermedades Mandibulares/patología , Neovascularización Patológica/tratamiento farmacológico , Ratas , Ratas Wistar , Selenio/uso terapéutico , Estreptozocina , Difracción de Rayos X
18.
Artículo en Inglés | MEDLINE | ID: mdl-7552851

RESUMEN

In recent years hyperbaric oxygen has gained an important role in the treatment of osteoradionecrosis of the mandible. In the treatment of 29 patients with osteoradionecrosis of the mandible, a combination of surgical debridement, antibiotics, and hyperbaric oxygen was used in 27 cases. In 20 of the 29 patients the osteoradionecrosis was considered to be resolved after treatment. In 31% of the patients, the continuity of the mandible was lost. It was concluded that combined treatment of surgical debridement, antibiotics, and hyperbaric oxygen gives acceptable results and may, when used in an early phase of the disease, limit the number of patients who lose continuity of the mandible.


Asunto(s)
Oxigenoterapia Hiperbárica , Enfermedades Mandibulares/terapia , Osteorradionecrosis/terapia , Adulto , Anciano , Carcinoma de Células Escamosas/radioterapia , Terapia Combinada , Femenino , Humanos , Masculino , Enfermedades Mandibulares/tratamiento farmacológico , Enfermedades Mandibulares/cirugía , Persona de Mediana Edad , Neoplasias de la Boca/radioterapia , Osteorradionecrosis/tratamiento farmacológico , Osteorradionecrosis/cirugía , Estudios Retrospectivos , Neoplasias de las Glándulas Salivales/radioterapia , Neoplasias de la Tiroides/radioterapia , Resultado del Tratamiento
19.
Acta Stomatol Belg ; 87(2): 107-24, 1990 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-2256451

RESUMEN

It is argued that mandibular resorption can be considered as osteoporotic in nature. This calls for a systemic approach in its treatment. One aspect mostly neglected is the tendency of bone to bind calcium and phosphate ions. A direct measure for this tendency is the difference in pH between the bone extracellular fluid and blood plasma with octocalcium phosphate. Calculation of these degrees of saturation of about 2000 data of blood plasma compositions given in the literature learned that calcitonin injections, estrogen replacement and magnesium supplementation increase the tendency of bone to bind calcium and phosphate ions and, hence, should be used in the therapy of mandibular resorption and of bone resorption in general.


Asunto(s)
Resorción Ósea/tratamiento farmacológico , Enfermedades Mandibulares/tratamiento farmacológico , Osteoporosis/tratamiento farmacológico , Resorción Ósea/metabolismo , Huesos/metabolismo , Calcitonina/uso terapéutico , Calcio/metabolismo , Terapia de Reemplazo de Estrógeno , Femenino , Humanos , Magnesio/uso terapéutico , Masculino , Osteoporosis/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA